[go: up one dir, main page]

BR9810620A - Terapia de bloqueio de cd154 para transplante de tecido da ilhota pancreática - Google Patents

Terapia de bloqueio de cd154 para transplante de tecido da ilhota pancreática

Info

Publication number
BR9810620A
BR9810620A BR9810620-1A BR9810620A BR9810620A BR 9810620 A BR9810620 A BR 9810620A BR 9810620 A BR9810620 A BR 9810620A BR 9810620 A BR9810620 A BR 9810620A
Authority
BR
Brazil
Prior art keywords
graft
compositions
processes
tissue transplantation
pancreatic islet
Prior art date
Application number
BR9810620-1A
Other languages
English (en)
Inventor
Norma S Kenyon
Camillo Ricordi
David W Thomas
Linda Burkly
Original Assignee
Biogen Inc
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Univ Miami filed Critical Biogen Inc
Publication of BR9810620A publication Critical patent/BR9810620A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)

Abstract

Patente de Invenção: <B>"TERAPIA DE BLOQUEIO DE CD154 PARA TRANSPLANTE DE TECIDO DA ILHOTA PANCREáTICA"<D>. Processos e composições para inibir a rejeição de tecido produtor de insulina em um receptor de enxerto, assim como processos e composições para prolongar a sobrevivência ou função do enxerto; para reverter a rejeição do enxerto ou restaurar a função de um enxerto deteriorado; e, para indução de tolerância imunológica ao tecido produtor de insulina enxertado. Os presentes processos e composições são adequados para tratamento e profilaxia de defeitos no controle metabólico da homeostase da glicose no sangue, incluindo defeitos manifestados na forma de diabetes melitus (DM).
BR9810620-1A 1997-06-20 1998-06-19 Terapia de bloqueio de cd154 para transplante de tecido da ilhota pancreática BR9810620A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5026797P 1997-06-20 1997-06-20
US7726598P 1998-03-09 1998-03-09
PCT/US1998/012892 WO1998058669A2 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for pancreatic islet tissue transplantation

Publications (1)

Publication Number Publication Date
BR9810620A true BR9810620A (pt) 2000-10-03

Family

ID=26728084

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810620-1A BR9810620A (pt) 1997-06-20 1998-06-19 Terapia de bloqueio de cd154 para transplante de tecido da ilhota pancreática

Country Status (21)

Country Link
US (2) US20030072754A1 (pt)
EP (1) EP1051191B1 (pt)
JP (1) JP2002506446A (pt)
KR (1) KR100634847B1 (pt)
CN (2) CN1195546C (pt)
AT (1) ATE339966T1 (pt)
AU (1) AU730763B2 (pt)
BG (1) BG64976B1 (pt)
BR (1) BR9810620A (pt)
CA (1) CA2294154A1 (pt)
DE (1) DE69835965T2 (pt)
EA (1) EA002550B1 (pt)
EE (1) EE9900588A (pt)
HU (1) HUP0003160A3 (pt)
IL (1) IL133303A0 (pt)
IS (1) IS5273A (pt)
NO (1) NO996275L (pt)
NZ (1) NZ502052A (pt)
SK (1) SK180299A3 (pt)
TR (1) TR199903142T2 (pt)
WO (1) WO1998058669A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045958A1 (en) * 1998-03-09 1999-09-16 Biogen, Inc. Cd154 blockade therapy for modulation of immune responses to implanted devices
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001275186A1 (en) * 2000-06-02 2001-12-17 Nicole Kirchhof Immunotherapeutic method to prevent islet cell rejection
IL152316A0 (en) * 2000-06-09 2003-05-29 Bristol Myers Squibb Co Pharmaceutical compositions and kits for treating transplant rejection
JP4667383B2 (ja) * 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
JP2008520235A (ja) * 2004-11-22 2008-06-19 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド インスリンを産生可能な拡大され、かつ再分化した成体島β細胞の集団およびその作製方法
WO2007047539A2 (en) * 2005-10-14 2007-04-26 Medtronic, Inc. Localized delivery to the lymphatic system
US8636995B2 (en) 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8911739B2 (en) 2009-02-10 2014-12-16 Trustees Of Columbia University In The City Of New York Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with Hsp60sp peptide
US9527912B2 (en) 2010-05-17 2016-12-27 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10147463B2 (en) 2014-12-10 2018-12-04 Nxp Usa, Inc. Video processing unit and method of buffering a source video stream
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
US10986309B2 (en) 2015-06-30 2021-04-20 Nxp Usa, Inc. Video buffering and frame rate doubling device and method
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
JP4751493B2 (ja) * 1996-03-20 2011-08-17 ブリストル−マイヤーズ スクイッブ カンパニー Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物

Also Published As

Publication number Publication date
HK1033548A1 (en) 2001-09-07
EA200000058A1 (ru) 2000-08-28
BG104091A (en) 2000-10-31
EP1051191B1 (en) 2006-09-20
CN1261286A (zh) 2000-07-26
EP1051191A2 (en) 2000-11-15
IS5273A (is) 1999-11-26
WO1998058669A3 (en) 1999-04-29
CN1651919A (zh) 2005-08-10
TR199903142T2 (xx) 2000-09-21
EA002550B1 (ru) 2002-06-27
SK180299A3 (en) 2000-06-12
HUP0003160A3 (en) 2002-09-30
NO996275D0 (no) 1999-12-17
JP2002506446A (ja) 2002-02-26
WO1998058669A2 (en) 1998-12-30
US20030072754A1 (en) 2003-04-17
CA2294154A1 (en) 1998-12-30
ATE339966T1 (de) 2006-10-15
KR100634847B1 (ko) 2006-10-17
NO996275L (no) 2000-02-21
CN1195546C (zh) 2005-04-06
IL133303A0 (en) 2001-04-30
EE9900588A (et) 2000-08-15
KR20010013965A (ko) 2001-02-26
US20070292440A1 (en) 2007-12-20
AU7983098A (en) 1999-01-04
DE69835965D1 (de) 2006-11-02
NZ502052A (en) 2001-01-26
BG64976B1 (bg) 2006-11-30
AU730763B2 (en) 2001-03-15
HUP0003160A2 (hu) 2001-01-29
DE69835965T2 (de) 2007-06-14

Similar Documents

Publication Publication Date Title
BR9810620A (pt) Terapia de bloqueio de cd154 para transplante de tecido da ilhota pancreática
Webb et al. Mechanism of membrane stabilization by calcium in vascular smooth muscle
Clyman et al. The role of calcium in regulation of cyclic nucleotide content in human umbilical artery.
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
Hoshi et al. Comparative endocrinology-paracrinology-autocrinology of human adult large vessel endothelial and smooth muscle cells
Ismail et al. Do changes in body temperature following envenomation by the scorpion Leiurus quinquestriatus influence the course of toxicity?
Wogensen et al. Functional and morphological effects of interleukin-1β on the perfused rat pancreas
BR0316666A (pt) Novo uso de sulfato de dextrano
Panet et al. Fibroblast growth factor induces a transient net K+ influx carried by the bumetanide-sensitive transporter in quiescent BALB/c 3T3 fibroblasts
FR2679775A1 (fr) Medicament a base de derives soufres neutralises.
Altura et al. Pentobarbital sodium inhibits calcium uptake in vascular smooth muscle
WO2002094744A3 (en) Compositions comprising d-chiro inositol and sulfonylureas and methods of treatment thereof
Turlapaty et al. Tris (hydroxymethyl) aminomethane inhibits calcium uptake in vascular smooth muscle
IL95046A0 (en) Substituted 2-imidazolines and pharmaceutical compositions containing them
DK0821593T3 (da) Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein
O'Hare et al. Evidence of increased parathyroid activity on discontinuation of high-aluminum dialysate in patients undergoing hemodialysis
Brewster et al. Heparin-independent mitogenicity in an endothelial and smooth muscle cell chimeric growth factor (S130K-HBGAM)
Campeau Survival following aortocoronary bypass graft surgery
EP1754490A3 (en) CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
Shunt References and Reviews
ZHAO et al. PROLONGATION OF SKIN ALLOGRAFT SURVIVAL BY TOPICAL USE OF CYC-LOSPORINE A (CsA)
Popoff et al. Calcitonin inhibits accumulation of cyclic AMP in stimulated peritoneal macrophages from normal rats but not from osteopetrotic (incisors-absent) littermates
SHIMADA et al. Absence of interactions between histidine-rich glycoprotein and heparin-like compounds on cultured porcine aortic endothelial cells
Groth et al. Diabetic patients subjected to combined pancreas and kidney transplantation or kidney transplantation alone: Outcome after 5 to 10 years
Nicholson et al. Renal transplantation from living related donors in Barbados

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: UNIVERSITY OF MIAMI (US) , BIOGEN IDEC MA, INC. (U

Free format text: ALTERADO DE: BIOGEN, INC.

B25D Requested change of name of applicant approved

Owner name: UNIVERSITY OF MIAMI (US) , BIOGEN IDEC MA INC. (US

Free format text: ALTERADO DE: BIOGEN IDEC MA, INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 37 DA LEI 9279/96, INDEFIRO O PRESENTE PEDIDO COM BASE NO ARTIGO 8O EM COMBINACAO COM O ARTIGO 13 E ARTIGO 25 DA LEI 9279/96.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.